KBC Securities - Hyloris Pharmaceuticals (HYL) Morning Notes : HYL BB

Report

KBC Securities

Hilde Van Boxstael ...

Jacob Mekhael
Thomas Couvreur

Morning Notes : HYL BB

: HYL BB

31/03/2025 1 EN

Underlying

Hyloris Pharmaceuticals

See profile

BE0974363955 Euronext Brussels Belgium

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Hilde Van Boxstael

Jacob Mekhael

Thomas Couvreur

Other Reports on these Companies

KBC Securities

Morning Notes : ARCAD NA, GIMB BB, HYL BB, CTPNV NA

: ARCAD NA, GIMB BB, HYL BB, CTPNV NA

January 20, 2026 January 20, 2026 1 EN

KBC Securities

Morning Notes : HYL BB

: HYL BB

December 31, 2025 December 31, 2025 1 EN

KBC Securities

Morning Notes : HYL BB

: HYL BB

December 30, 2025 December 30, 2025 1 EN

Morning Notes : ABN NA, AD NA, HEIA NA, LOTB BB, RAND NA, ALFEN NA, PHVS US

: ABN NA, AD NA, HEIA NA, LOTB BB, RAND NA, ALFEN NA, PHVS US

5h / 55m 5h / 55m 1 EN

Wim Hoste

Wim Hoste

Heineken FIRST LOOK: FY25 operating profit +4.4%, FY26 guidance of 2-6% growth

Heineken's FY25 top line and operating profit figures were slightly better than our forecasts with operating profit in absolute terms in line with consensus. Heineken guides again for sizeable savings efforts in FY26 with operating profit growth guidance calling for a 2-6% range (vs our and consensus forecasts of c. 5%). We still appreciate Heineken for the sizeable self-help initiatives which should support organic earnings growth in the coming years, but acknowledge that the bumpier volume evolution of the past few years makes the investment case a bit less predictable and hence also less ap...

6h / 21m 6h / 21m 1 EN

Mathijs Geerts Danau

Mathijs Geerts Danau

Pharvaris To present clinical data at the AAAAI 2026

Pharvaris will present multiple datasets at AAAAI 2026, including topline RAPIDe-3 results, final CHAPTER-1 data, supporting evidence for the extended-release formulation, AMRA endpoint validation, and results from a new kinin biomarker assay. We look forward to the prophylactic phase 3 (CHAPTER-3) readout in 3Q26 and reiterate our Buy and $ 36 TP.

6h / 41m 6h / 41m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Morning Notes : HYL BB

We are a financial services provider for several types of professional clients, each with distinct needs.

Morning Notes : ARCAD NA, GIMB BB, HYL BB, CTPNV NA

Morning Notes : HYL BB

Morning Notes : HYL BB

Morning Notes : ABN NA, AD NA, HEIA NA, LOTB BB, RAND NA, ALFEN NA, PHVS US

Heineken FIRST LOOK: FY25 operating profit +4.4%, FY26 guidance of 2-6% growth

Pharvaris To present clinical data at the AAAAI 2026

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe